Paul Hudson, CEO of Sanofi, has been driving an all-encompassing effort to use AI to reshape the way the company ...

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong ...

Regeneron-partnered Dupixent, the crown jewel of Sanofi’s commercial portfolio, continued to impress with 21.1% sales growth ...

For now, Sanofi’s U.S. inventory is insulating the company from a potential 15% tariff on drugs shipped from the EU.

Sanofi rode the growing sales wave for blockbuster immunology drug Dupixent (dupilumab) in Q2 but reported ...

Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was revised upward.

French pharmaceutical giant Sanofi reported a sharp increase in second-quarter profit on Thursday, driven by higher net sales ...

Although Sanofi delivered an earnings miss which still had encouraging results, SNY stock tanked, offering a potential ...

Paul Hudson, Sanofi's CEO, said at the time, "The proposed acquisition of Blueprint Medicines represents a strategic step forward in our rare and immunology portfolios. It enhances our pipeline and ...

Immunology is an increasingly competitive space, which puts significant pressure on Sanofi to develop a pipeline that could replace Dupixent over the next 10 years. Sanofi's late-stage pipeline ...

Hello, everyone. This is Thomas Kudsk Larsen from the Sanofi IR team. Welcome to the Q2 2025 conference call for investors ...

Sanofi’s entrenched vaccine and rare-disease franchises add to its competitive advantages, stemming from efficient scale in some rare-disease drugs and cost advantages in the vaccines division.